Drugs / Cofrogliptin
Cofrogliptin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04556851 | Sep 2020 → Jan 2022 | type 2 diabetes mellitus | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT07019012 | Jul 2025 → Oct 2026 expected | type 2 diabetes mellitus | Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07460336 | May 2026 → Dec 2027 expected | latent autoimmune diabetes in adults | Second Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| — | NCT07122102 | Oct 2025 → Jun 2027 expected | type 2 diabetes mellitus | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06863532 Comparator | Mar 2025 → Jun 2026 overdue | type 2 diabetes mellitus | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cofrogliptin | “cofrogliptin (HSK7653), a novel long-acting dipeptidyl peptidase-4 inhibitor” PMID 39434431 ↗ Oct 2024 |
| Known as | Cofrogliptina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4646510 ↗ |
| Known as | Cofrogliptine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4646510 ↗ |
| Known as | Haisco hsk 7653 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4646510 ↗ |
| Known as | HSK7653 | “cofrogliptin (HSK7653), a novel long-acting dipeptidyl peptidase-4 inhibitor” PMID 39434431 ↗ Oct 20241“Cofrogliptin （HSK7653）” NCT07122102 ↗ |
| Action | Inhibit | “Cofrogliptin is a novel, ultra-long-acting DPP-4 inhibitor.” NCT07460336 ↗ |
| Modality | Small molecule | — CHEMBL4646510 ↗ |
| Route | Oral | “HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet), Q2W, oral” NCT04556851 ↗ |